Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novo-Nordisk A/S

66.77
+1.852.84%
Volume:8.11M
Turnover:538.91M
Market Cap:296.37B
PE:19.63
High:66.96
Open:65.52
Low:65.45
Close:64.92
Loading ...

Sector Update: Health Care Stocks Gain Wednesday Afternoon

MT Newswires Live
·
08 May

Earnings Movers: Porch Group Soars 44%; Disney up 10%; TripAdvisor up 9%; Teva Pharma up 7%; Upstart down 13%; Marvell down 10%; Uber Sinks 4%

Tiger Newspress
·
07 May

Novo Nordisk Drops Gender Representation Goals in US

MT Newswires Live
·
07 May

Novo Nordisk Predicts Strong Second Half

Motley Fool
·
07 May

Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook

Benzinga
·
07 May

Novo Nordisk Shares Jump 6% as Wegovy Fuels Double-Digit Growth

GuruFocus
·
07 May

Bernstein Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

TIPRANKS
·
07 May

Ozempic maker Novo Nordisk cuts its profit outlook

Dow Jones
·
07 May

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

Dow Jones
·
07 May

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

Dow Jones
·
07 May

Novo Nordisk Gains 6.5% Premarket as CFO Touts Wegovy's Rebound Potential

Bloomberg
·
07 May

Stock Track | Novo Nordisk Soars 6.44% Pre-market on Strong Q1 Earnings, Despite Lowered Outlook

Stock Track
·
07 May

Novo Nordisk shares are rising after the company cut its outlook. It's been that kind of year.

Dow Jones
·
07 May

Stock Track | Novo Nordisk Soars 5.07% as Q1 Earnings Beat Estimates, Aggressive Market Share Strategy Pays Off

Stock Track
·
07 May

Novo Nordisk Cuts 2025 Outlook as Wegovy Obesity Drug Sales Slow

Reuters
·
07 May

Novo Nordisk A/S reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

Dow Jones
·
07 May

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

Dow Jones
·
07 May

Novo Nordisk Lowers 2025 Outlook: Sales Growth Now Seen At 13–21% (Prior 16%–24%) At CER and Operating Profit at 16–24% (Priro 19%–27%) At CER, Citing Weaker Branded GLP-1 Uptake Amid Rapid US Compounding Expansion

Benzinga
·
07 May

Novo Nordisk Q1 EPS $0.92 Beats $0.90 Estimate, Sales $10.89B Miss $11.64B Estimate

Benzinga
·
07 May